Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258149 | 0.83 | L3MBTL1 (0.44) | L3MBTL1HTR2AHTR2CSLC6A4NPC1 | |
| SCHEMBL4255068 | 0.82 | L3MBTL1 (0.39) | L3MBTL1HTR2AHTR2CSLC6A4NPC1 | |
| SCHEMBL4263016 | 0.77 | L3MBTL1 (0.45) | L3MBTL1HTR2AHTR2CSLC6A4NPC1 | |
| SCHEMBL4265633 | 0.72 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL4255054 | 0.69 | L3MBTL1 (0.33) | L3MBTL1NPC1RAB9A | |
| SCHEMBL5199433 | 0.67 | KDM4C (0.38) | L3MBTL1NPC1RAB9A | |
| SCHEMBL5013687 | 0.66 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL7674634 | 0.65 | L3MBTL1 (0.40) | L3MBTL1NPC1RAB9A | |
| SCHEMBL3466586 | 0.63 | L3MBTL1 (0.38) | L3MBTL1SLC6A4NPC1RAB9A | |
| SCHEMBL7676368 | 0.61 | MEN1 (0.38) | L3MBTL1SLC6A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | L3MBTL1 4844/4885HTR2A 88/4885HTR2C 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.